Edward L Barnes1,2,3, Christina M Bauer1,2, Robert S Sandler1,3, Michael D Kappelman2,3,4, Millie D Long1,2,3. 1. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3. Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 4. Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract
BACKGROUND: Prior studies have identified racial disparities in the treatment and outcomes of inflammatory bowel disease (IBD). These disparities could be secondary to differences in biology, care delivery, or access to appropriate therapy. The primary aim of this study was to compare medication use among Medicaid-insured black and white patients with IBD, given uniform access to gastroenterologists and therapies. METHODS: We analyzed Medicaid Analytic eXtract data from 4 states (California, Georgia, North Carolina, and Texas) between 2006 and 2011. We compared the use of IBD-specific therapies, including analyses of postoperative therapy among patients with Crohn disease (CD). We performed bivariate analyses and multivariable logistic regression, adjusting for potential confounders. RESULTS: We identified 14,735 patients with IBD (4672 black [32%], 8277 with CD [58%]). In multivariable analysis, there was no significant difference in the odds of anti-tumor necrosis factor use by race for CD (adjusted odds ratio [aOR] = 1.13; 95% confidence interval [CI], 0.99-1.28] or ulcerative colitis (aOR = 1.12; 95% CI, 0.96-1.32). Black patients with CD were more likely than white patients to receive combination therapy (aOR = 1.50; 95% CI, 1.15-1.96), and black patients were more likely than white patients to receive immunomodulator monotherapy after surgery for CD (31% vs 18%; P = 0.004). CONCLUSIONS: In patients with Medicaid insurance, where access to IBD-specific therapy should be similar for all individuals, there was no significant disparity by race in the utilization of IBD-specific therapies. Disparities in IBD treatment discussed in prior literature seem to be driven by socioeconomic or other issues affecting access to care.
BACKGROUND: Prior studies have identified racial disparities in the treatment and outcomes of inflammatory bowel disease (IBD). These disparities could be secondary to differences in biology, care delivery, or access to appropriate therapy. The primary aim of this study was to compare medication use among Medicaid-insured black and white patients with IBD, given uniform access to gastroenterologists and therapies. METHODS: We analyzed Medicaid Analytic eXtract data from 4 states (California, Georgia, North Carolina, and Texas) between 2006 and 2011. We compared the use of IBD-specific therapies, including analyses of postoperative therapy among patients with Crohn disease (CD). We performed bivariate analyses and multivariable logistic regression, adjusting for potential confounders. RESULTS: We identified 14,735 patients with IBD (4672 black [32%], 8277 with CD [58%]). In multivariable analysis, there was no significant difference in the odds of anti-tumor necrosis factor use by race for CD (adjusted odds ratio [aOR] = 1.13; 95% confidence interval [CI], 0.99-1.28] or ulcerative colitis (aOR = 1.12; 95% CI, 0.96-1.32). Black patients with CD were more likely than white patients to receive combination therapy (aOR = 1.50; 95% CI, 1.15-1.96), and black patients were more likely than white patients to receive immunomodulator monotherapy after surgery for CD (31% vs 18%; P = 0.004). CONCLUSIONS: In patients with Medicaid insurance, where access to IBD-specific therapy should be similar for all individuals, there was no significant disparity by race in the utilization of IBD-specific therapies. Disparities in IBD treatment discussed in prior literature seem to be driven by socioeconomic or other issues affecting access to care.
Authors: Conor G Loftus; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; L Joseph Melton; William J Sandborn Journal: Inflamm Bowel Dis Date: 2007-03 Impact factor: 5.325
Authors: Dan Li; Bernadette Collins; Fernando S Velayos; Liyan Liu; James D Lewis; James E Allison; Nicole T Flowers; Susan Hutfless; Oren Abramson; Lisa J Herrinton Journal: Dig Dis Sci Date: 2013-10-31 Impact factor: 3.199
Authors: Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Ming-Hsi Wang; Lisa W Datta; Steven R Brant Journal: Am J Gastroenterol Date: 2010-05-18 Impact factor: 10.864
Authors: David T Rubin; Lauren D Feld; Sarah R Goeppinger; Joel Margolese; Joel Rosh; Michele Rubin; Sandra Kim; Dylan M Rodriquez; Laura Wingate Journal: Inflamm Bowel Dis Date: 2017-02 Impact factor: 5.325
Authors: Steven R Brant; David T Okou; Claire L Simpson; David J Cutler; Talin Haritunians; Jonathan P Bradfield; Pankaj Chopra; Jarod Prince; Ferdouse Begum; Archana Kumar; Chengrui Huang; Suresh Venkateswaran; Lisa W Datta; Zhi Wei; Kelly Thomas; Lisa J Herrinton; Jan-Micheal A Klapproth; Antonio J Quiros; Jenifer Seminerio; Zhenqiu Liu; Jonathan S Alexander; Robert N Baldassano; Sharon Dudley-Brown; Raymond K Cross; Themistocles Dassopoulos; Lee A Denson; Tanvi A Dhere; Gerald W Dryden; John S Hanson; Jason K Hou; Sunny Z Hussain; Jeffrey S Hyams; Kim L Isaacs; Howard Kader; Michael D Kappelman; Jeffry Katz; Richard Kellermayer; Barbara S Kirschner; John F Kuemmerle; John H Kwon; Mark Lazarev; Ellen Li; David Mack; Peter Mannon; Dedrick E Moulton; Rodney D Newberry; Bankole O Osuntokun; Ashish S Patel; Shehzad A Saeed; Stephan R Targan; John F Valentine; Ming-Hsi Wang; Martin Zonca; John D Rioux; Richard H Duerr; Mark S Silverberg; Judy H Cho; Hakon Hakonarson; Michael E Zwick; Dermot P B McGovern; Subra Kugathasan Journal: Gastroenterology Date: 2016-09-28 Impact factor: 22.682
Authors: Edward L Barnes; Bharati Kochar; Millie D Long; Christopher F Martin; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2017-12 Impact factor: 7.290